国信证券发布特宝生物研报，2025上半年归母净利润同比增长41%，长效生长激素产品获批上市

Group 1 - The core viewpoint of the report is that Teabo Bio (688278.SH) is rated as "better than market" due to its rapid revenue and net profit growth [2] - The company has shown an improvement in net profit margin and a continuous decrease in sales expense ratio [2] - The approval of long-acting growth hormone products for market launch is a significant milestone for the company [2]